Lamotrigine in pregnancy and lactation: A case report

被引:106
作者
Tomson, T
Ohman, I
Vitols, S
机构
[1] KAROLINSKA HOSP,DEPT CLIN NEUROSCI,NEUROL SECT,S-10401 STOCKHOLM,SWEDEN
[2] KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN PHARMACOL,S-10401 STOCKHOLM,SWEDEN
关键词
epilepsy; pregnancy; lamotrigine; pharmacokinetics; breast milk;
D O I
10.1111/j.1528-1157.1997.tb01489.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: We investigated the effect of pregnancy on the kinetics of lamotrigine (LTG), passage of LTG over the placenta and the excretion of the drug in breast milk. Methods: We used high-performance liquid chromatography to determine concentrations of LTG in plasma and in breast milk in a woman who was treated with LTG monotherapy during pregnancy and lactation. Results: Plasma levels of LTG decreased as pregancy progressed. The ratio of dose to plasma concentration was 5.8 times higher at delivery and 3.6 times higher in late pregnancy as compared with 5 months postpartum, suggesting enhanced clearance of LTG during pregnancy. The concentration ratio of umbilical cord to mother's plasma was 1.2 indicating extensive passage of LTG over the placenta. The LTG plasma concentration in the newborn was still 48 h after birth similar to the plasma levels of the mother at delivery and in the umbilical cord. The ratio of milk to plasma concentration was 0.6 2 weeks after delivery and the plasma concentration in the breastfed child was 25% of the mother's plasma levels. No adverse effects were observed in the newborn. Conclusions: The kinetics of LTG may be influenced by pregnancy to such a degree that dose adjustments may be indicated. Due to an extensive passage of LTG into breast milk, and a slow elimination in the newborn, LTG concentrations in the nursed infant may reach levels at which pharmacological effects can be expected.
引用
收藏
页码:1039 / 1041
页数:3
相关论文
共 11 条
[1]   PRINCIPLES OF DRUG BIODISPOSITION IN THE NEONATE - A CRITICAL-EVALUATION OF THE PHARMACOKINETIC-PHARMACODYNAMIC INTERFACE .1. [J].
BESUNDER, JB ;
REED, MD ;
BLUMER, JL .
CLINICAL PHARMACOKINETICS, 1988, 14 (04) :189-216
[2]  
Eldridge Robbin R., 1995, Epilepsia, V36, P90
[3]   Liquid chromatographic determination of plasma lamotrigine in pediatric samples [J].
Forssblad, E ;
Eriksson, AS ;
Beck, O .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (06) :755-758
[4]   Concentration-effect and concentration-toxicity relations with lamotrigine: A prospective study [J].
Kilpatrick, ES ;
Forrest, G ;
Brodie, MJ .
EPILEPSIA, 1996, 37 (06) :534-538
[5]  
Parsons Derrick N., 1995, P877
[6]   Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child [J].
Rambeck, B ;
Kurlemann, G ;
Stodieck, SRG ;
May, TW ;
Jurgens, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 51 (06) :481-484
[7]   LAMOTRIGINE CLINICAL PHARMACOKINETICS [J].
RAMBECK, B ;
WOLF, P .
CLINICAL PHARMACOKINETICS, 1993, 25 (06) :433-443
[8]   EPILEPSY AND PREGNANCY - A PROSPECTIVE-STUDY OF SEIZURE CONTROL IN RELATION TO FREE AND TOTAL PLASMA-CONCENTRATIONS OF CARBAMAZEPINE AND PHENYTOIN [J].
TOMSON, T ;
LINDBOM, U ;
EKQVIST, B ;
SUNDQVIST, A .
EPILEPSIA, 1994, 35 (01) :122-130
[9]   DISPOSITION OF CARBAMAZEPINE AND PHENYTOIN IN PREGNANCY [J].
TOMSON, T ;
LINDBOM, U ;
EKQVIST, B ;
SUNDQVIST, A .
EPILEPSIA, 1994, 35 (01) :131-135
[10]   PROBLEMS AND MANAGEMENT OF THE PREGNANT WOMAN WITH EPILEPSY [J].
YERBY, MS .
EPILEPSIA, 1987, 28 :S29-S36